

1 **Practical challenges to the clinical implementation of saliva for SARS-CoV-2 detection**

2

3 Nancy Matic^{1,2}, Aleksandra Stefanovic^{1,2}, Victor Leung^{1,2}, Tanya Lawson¹, Gordon Ritchie^{1,2},

4 Lynne Li², Sylvie Champagne^{1,2}, Marc G. Romney^{1,2}, Christopher F. Lowe^{1,2}

5 ¹ Division of Medical Microbiology and Virology, St. Paul's Hospital, Vancouver, Canada

6 ² Department of Pathology and Laboratory Medicine, University of British Columbia,

7 Vancouver, Canada

8

9 **Key Words:** Saliva; diagnostics; SARS-CoV-2

10

11 **Abstract**

12 Due to global shortages of flocked nasopharyngeal swabs and appropriate viral transport media
13 during the COVID-19 pandemic, alternate diagnostic specimens for SARS-CoV-2 detection are
14 sought. The accuracy and feasibility of saliva samples collected and transported without
15 specialized collection devices or media were evaluated. Saliva demonstrated good concordance
16 with paired nasopharyngeal swabs for SARS-CoV-2 detection in 67/74 cases (90.5%), though
17 barriers to saliva collection were observed in long-term care residents and outbreak settings.
18 SARS-CoV-2 RNA was stable in human saliva at room temperature for up to 48 hours after
19 initial specimen collection, informing appropriate transport time and conditions.

20

21

22

23

24 **Introduction**

25 Diagnostic testing is a cornerstone of the COVID-19 pandemic response strategy[1], yet the
26 establishment of laboratory testing which is accurate, practical, and scalable to meet demand for
27 public health surveillance measures has been a considerable challenge. Nasopharyngeal swabs
28 are the preferred specimen type over throat swabs due to superior sensitivity[2,3], and over nasal
29 aspirates due to lower risk of aerosol generation. Flocked nasopharyngeal swabs are designed to
30 maximize mucosal contact and more efficiently release contents into the testing medium[4,5];
31 however, due to global demand during the pandemic response, a reliable supply of high-quality,
32 flocked swabs and appropriate viral transport medium has been difficult to procure.
33 Furthermore, studies describe variable collection quality of nasopharyngeal specimens leading to
34 diminished sensitivity and potential false-negative results for SARS-CoV-2[6–8]. Although
35 samples from the lower respiratory tract such as sputum or bronchoalveolar lavage have been
36 widely used[9–11], only a subset of patients under investigation for COVID-19 are able to
37 expectorate sputum or undergo invasive bronchoscopic procedures.
38 Saliva has been described as an acceptable alternative diagnostic specimen for detection of
39 common respiratory viruses[12–15], and more recently, SARS-CoV-2[6,16–19]. Salivary gland
40 epithelial cells have demonstrated high expression of ACE2 receptors[20,21], which may
41 enhance the replication of SARS-CoV-2 at this site. Collection techniques vary widely in the
42 published medical literature, and include: passively drooling into a 50mL Falcon tube for one
43 minute[16]; coughing 0.5-1mL of saliva from the back of the throat into a sterile container and
44 adding 2mL of viral transport media upon receipt in the laboratory[17,18]; repeatedly spitting
45 into a sterile container upon waking in the morning prior to eating, drinking, or brushing

46 teeth[6]; or pooling 1-2mL of saliva into a container with addition of liquid Amies media in a 1:1
47 ratio upon receipt in the laboratory[19].

48 Saliva collection techniques which require transport media or specialized collection devices are
49 problematic during a pandemic. Distribution of pre-packaged kits may be costly and impractical
50 for community settings, and the reliable supply of necessary materials will continue to be a
51 global challenge. Specialized saliva collection devices typically marketed for biochemical
52 tests[22] may contain components such as cotton which can inhibit nucleic acid amplification.
53 Furthermore, it is uncertain in the current medical literature whether the enzymatic properties of
54 human saliva will readily degrade intact virus particles from infected patients, as opposed to
55 naked viral RNA[23,24]. Commercial RNA stabilization solutions have been marketed to
56 preserve cellular RNA in various specimen types, yet have also been described to decrease
57 efficiency of nucleic acid extraction[25,26]. Clinical diagnostic laboratories require immediate
58 guidance for implementing practical and feasible methods of saliva collection, transport and
59 processing for SARS-CoV-2 detection.

60

61 **Materials and Methods**

62 From March-May 2020, saliva and nasopharyngeal swabs were received from patients under
63 investigation for COVID-19 from various clinical settings: symptomatic patients requiring
64 admission to a tertiary acute care hospital; residents of long-term care (LTC) facilities with
65 known COVID-19 outbreaks; healthcare workers; and mildly symptomatic outpatients including
66 household contacts of known positive cases. After the nasopharyngeal swab was collected,
67 patients were asked to provide approximately 1mL of saliva by pooling saliva from their throat
68 and spitting into a sterile screw-top container (Starplex Scientific Inc., Etobicoke, Canada).

69 Saliva samples were transported to the laboratory at room temperature without addition of
70 transport media, with routine transport times (<24 hours). Upon receipt in the laboratory,
71 samples were diluted 1:2 with sterile phosphate-buffered saline (PBS) and vortexed with glass
72 beads until liquid consistency was achieved. Saliva samples were stored at 4°C until nucleic
73 acid extraction could be performed (<24 hours from time of specimen receipt). Nucleic acid
74 extraction was completed using the MagNA Pure Compact or MagNA Pure 96 System (Roche
75 Molecular Diagnostics, California, USA). Molecular detection of the SARS-CoV-2 envelope (E)
76 gene from saliva samples was performed with the LightMix® ModularDx SARS-CoV
77 (COVID19) E-gene assay (TIB Molbiol, Germany) and LightCycler® Multiplex RNA Virus
78 Master (Roche Molecular Diagnostics, California, USA).

79 To investigate the optimal transport time of saliva samples without the use of transport media,
80 the stability of SARS-CoV-2 RNA detectable in human saliva samples over time was evaluated.
81 Two patients known to be positive for SARS-CoV-2 and three healthy volunteers provided five
82 saliva samples each. The saliva from volunteers was spiked with 50µL of remnant viral
83 transport media (BD™ universal viral transport system, Maryland, USA) from the
84 nasopharyngeal swabs of SARS-CoV-2 positive patients (Cycle threshold [Ct] value 15-16 for E-
85 gene). Saliva from the patients and volunteers was processed as previously described, but an
86 aliquot of each sample was processed at delayed time points: 0, 12, 24, 36 and 48 hours. In the
87 interim, saliva was stored at room temperature to mirror typical transport conditions. SARS-
88 CoV-2 detection was performed as previously described in triplicate for each sample and mean
89 Ct values were compared over time.

90

91 **Results**

92 One hundred and six (106) saliva specimens were received from patients under investigation for
93 COVID-19. Thirty-one saliva specimens (29.2%) had negligible sample volume (<0.5mL). The
94 majority of saliva samples with insufficient volume were from residents and healthcare workers
95 of a LTC facility (30/31, 96.8%). One further specimen was excluded from the analysis due to
96 its appearance as expectorated sputum. On average, the approximate time from saliva collection
97 to the time of laboratory processing was 13 hours for inpatients, 16 hours for outpatients, and 19
98 hours for samples from LTC facilities. The final analysis included 13/74 samples from
99 inpatients (17.6%), 20/74 samples from LTC residents (27.0%), 28/74 samples from healthcare
100 workers (37.8%), and 13/74 samples from outpatients (17.6%). For the detection of SARS-CoV-
101 2, saliva was concordant with paired nasopharyngeal swabs in 67/74 cases (90.5%); in one case
102 (1.4%), saliva demonstrated detectable SARS-CoV-2 RNA where the paired nasopharyngeal
103 swab was negative.

104 Stability of SARS-CoV-2 viral RNA in saliva with delayed processing up to 36 hours was
105 demonstrated (Figure 1; mean Ct value for E-gene was 23.75 at time zero versus 24.16 at 36
106 hours; p-value 0.328, paired *t*-test, GraphPad™). The mean Ct value appeared to demonstrate a
107 significant increase at the last reading near 48 hours (25.76, p-value 0.014, paired *t*-test),
108 although this may be attributed to a single outlier sample (Patient 2), which was collected from
109 an outpatient and had the longest total transport time (53 hours) of all samples.

110

111 **Discussion**

112 As a diagnostic specimen for SARS-CoV-2 detection, saliva performed well and demonstrated
113 good general concordance with nasopharyngeal swabs. Although a minority of saliva samples
114 (6/74, 8.1%) were discordantly negative for SARS-CoV-2 RNA, the paired nasopharyngeal

115 swabs in these cases had evidence of low viral loads (late Ct values in the range of 31-39),
116 suggesting the decrease in sensitivity may be attributable to viral loads near the limit of detection
117 of the assay rather than the inherent properties of saliva.

118 Pre-analytical and analytical factors must be carefully considered before implementation of
119 saliva as a routine diagnostic specimen. Nearly 30% of saliva specimens in this study were of
120 insufficient volume. Although strategies to improve saliva collection have been described[6],
121 LTC residents may face particular challenges due to xerostomia, inability to follow commands,
122 or physical barriers with dentures. Furthermore, saliva may not be suitable for mass testing in
123 outbreak settings where sufficient time or instructions may not be provided. Importantly, the
124 findings from this study indicate saliva without transport media can be in transit at room
125 temperature for up to 48 hours prior to laboratory processing without losing diagnostic yield.

126 The amount of saliva processing required in the laboratory was significant. Manual labour by
127 laboratory technologists is required to decrease viscosity of saliva and ensure compatibility with
128 laboratory instruments, which has added operational cost. Addition of 1:2 PBS dilutes the
129 specimen and may affect diagnostic sensitivity. However, treatment of saliva in this manner is
130 necessary, as previous experiences in our laboratory revealed nearly all saliva samples
131 demonstrated inhibition with the LightMix® assay when run neat, requiring repeat testing and
132 delaying turn-around-time.

133 This study had several limitations. Firstly, due to a limited number of samples per each patient
134 group, we are not able to make inferences on performance in any one particular setting. Samples
135 were collected by various healthcare workers without specific training or instruction in saliva
136 collection, and submitted from diverse locations leading to variable transport times. However,
137 these factors do provide a realistic view of the utility of saliva samples in clinical settings. The

138 evaluation of the stability of SARS-CoV-2 viral RNA in human saliva samples without transport
139 media was limited to 48 hours by the available volume of saliva from patients and volunteers.
140 However, the vast majority of samples received by our laboratory for SARS-CoV-2 detection are
141 processed in less than 48 hours, and thus these results have relevance to many clinical diagnostic
142 laboratories.
143 Further study may include establishment of a reliable method for saliva collection in patient
144 populations with barriers (e.g., LTC residents, intubated patients in critical care units), and
145 optimization of high-throughput automated laboratory instruments to accommodate these highly
146 viscous specimens collected as part of mass surveillance measures.

147

148 **Acknowledgements**

149 We sincerely extend our gratitude to the patients and volunteers who contributed samples to this
150 study as part of the COVID-19 response. We thank Dr. Michael Schwandt and Noah Reich for
151 their contributions to this project. We are also indebted to our medical laboratory technologists
152 who are highly committed to patient care and laboratory quality improvement.

153 The authors have no relevant conflicts of interest to declare.

154

155

156

157

158

159

160

161 **References**

- 162 1. World Health Organization. 2019 Novel Coronavirus (2019-nCoV): Strategic
163 Preparedness and Response Plan. **2020**; :28. Available at:
164 [https://www.who.int/publications-detail/strategic-preparedness-and-response-plan-for-the-](https://www.who.int/publications-detail/strategic-preparedness-and-response-plan-for-the-new-coronavirus)
165 [new-coronavirus](https://www.who.int/publications-detail/strategic-preparedness-and-response-plan-for-the-new-coronavirus).
- 166 2. L Zou, F Ruan MH. SARS-CoV-2 viral load in upper respiratory specimens of infected
167 patients. *N Engl J Med* **2020**; 382:1177–1179.
- 168 3. Yang Y, Yang M, Shen C, et al. Evaluating the accuracy of different respiratory
169 specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV
170 infections. *medRxiv* **2020**; :2020.02.11.20021493.
- 171 4. Daley P, Castriciano S, Chernesky M, Smieja M. Comparison of flocked and rayon swabs
172 for collection of respiratory epithelial cells from uninfected volunteers and symptomatic
173 patients. *J Clin Microbiol* **2006**; 44:2265–2267.
- 174 5. Baron EJ, Miller JM, Weinstein MP, et al. A guide to utilization of the microbiology
175 laboratory for diagnosis of infectious diseases: 2013 recommendations by the infectious
176 diseases society of America (IDSA) and the American Society for Microbiology (ASM).
177 *Clin Infect Dis* **2013**; 57.
- 178 6. Wyllie AL, Fournier J, Casanovas-Massana A, et al. Saliva is more sensitive for SARS-
179 CoV-2 detection in COVID-19 patients than nasopharyngeal swabs. *medRxiv* **2020**;
180 :2020.04.16.20067835.
- 181 7. Qian Y, Zeng T, Wang H, et al. Safety management of nasopharyngeal specimen
182 collection from suspected cases of coronavirus disease 2019. *Int J Nurs Sci* **2020**; :10–13.
- 183 8. Kinloch N, Ritchie G, Brumme CJ, Dong W, Dong W, Lawson T, Jones RB, Montaner

- 184 JSG, Leung V, Romney MG, Stefanovic A, Matic N, Lowe CF BZ. Suboptimal biological
185 sampling as a probable cause of false-negative COVID-19 diagnostic test results. *J Infect*
186 *Dis* **2020**; :1–4.
- 187 9. Yan Y, Chang L, Wang L. Laboratory testing of SARS-CoV, MERS-CoV, and
188 SARS-CoV-2 (2019-nCoV): Current status, challenges, and countermeasures. *Rev Med*
189 *Viro* **2020**; :1–14.
- 190 10. US Centers for Disease Control and Prevention (CDC). Interim Guidelines for Collecting,
191 Handling, and Testing Clinical Specimens from Persons Under Investigation (PUIs) for
192 Coronavirus Disease 2019 (COVID-19). **2020**;
- 193 11. (WHO) WHO. Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected
194 human cases. **2020**;
- 195 12. Robinson JL, Lee BE, Kothapalli S, Craig WR, Fox JD. Use of Throat Swab or Saliva
196 Specimens for Detection of Respiratory Viruses in Children. *Clin Infect Dis* **2008**;
197 46:e61–e64.
- 198 13. Bartholomeusz A, Locarnini S. Associated With Antiviral Therapy. *Antivir Ther* **2006**;
199 55:52–55.
- 200 14. Kim YG, Yun SG, Kim MY, Park K, Cho CH, Yoon SY, Nsm MH, Lee CK, Cho YJ LC.
201 Comparison between saliva and nasopharyngeal swab specimens for detection of
202 respiratory viruses by multiplex reverse transcription-PCR. *J Clin Microbiol* **2017**;
203 55:226–233.
- 204 15. To KK, Lu L, Yip CC, et al. Additional molecular testing of saliva specimens improves
205 the detection of respiratory viruses. *Emerg Microbes Infect* **2017**; 6.
- 206 16. Azzi L, Carcano G, Gianfagna F, et al. SALIVA IS A RELIABLE TOOL TO DETECT

- 207 SARS-CoV-2. *J Infect* **2020**; :1–6.
- 208 17. To KKW, Tsang OTY, Chik-Yan Yip C, et al. Consistent detection of 2019 novel
209 coronavirus in saliva. *Clin Infect Dis* **2020**; :4–6.
- 210 18. To KKW, Tsang OTY, Leung WS, et al. Temporal profiles of viral load in posterior
211 oropharyngeal saliva samples and serum antibody responses during infection by SARS-
212 CoV-2: an observational cohort study. *Lancet Infect Dis* **2020**; 3099:1–10.
- 213 19. Williams E, Bond K, Zhang B, Putland M, Williamson DA. Saliva as a non-invasive
214 specimen for detection of SARS-CoV-2. *J Clin Microbiol* **2020**; 50.
- 215 20. Xu J, Li Y, Gan F, Du Y, Yao Y. Salivary Glands: Potential Reservoirs for COVID-19
216 Asymptomatic Infection. *J Dent Res* **2020**; :918518.
- 217 21. Li Y, Ren B, Peng X, et al. Saliva is a non-negligible factor in the spread of COVID-19.
218 *Mol Oral Microbiol* **2020**; :0–2.
- 219 22. Lenander-Lumikari M, Johansson I, Vilja P, Samaranayake L. Newer saliva collection
220 methods and saliva composition: a study of two Salivette® kits. *Oral Dis* **1995**; 1:86–91.
- 221 23. Fábryová H, Celec P. On the origin and diagnostic use of salivary RNA. *Oral Dis* **2014**;
222 20:146–152.
- 223 24. Park NJ, Li Y, Yu T, Brinkman BMN, Wong DT. Characterization of RNA in saliva. *Clin*
224 *Chem* **2006**; 52:988–994.
- 225 25. Rodríguez A, Vaneechoutte M. Comparison of the efficiency of different cell lysis
226 methods and different commercial methods for RNA extraction from *Candida albicans*
227 stored in RNAlater. *BMC Microbiol* **2019**; 19:1–10.
- 228 26. Jiang L, Li L, Kang P, et al. Inappropriateness of RNAlater to preserve *Caenorhabditis*
229 *elegans* for RNA extraction. *MethodsX* **2019**; 6:2460–2467. Available at:

230 <https://doi.org/10.1016/j.mex.2019.10.015>.

231

232

233

234

235

236

237

238

239

240

241


242

243

244

245

246



247

248 **Figure 1:** Saliva samples from patients with known COVID-19 infection or from healthy

249 volunteers spiked with viral transport media from the nasopharyngeal swabs of known positive

250 COVID-19 cases were held in the laboratory at room temperature and processed at different time

251 points. The stability of SARS-CoV-2 viral RNA in these samples is represented by the average

252 detected cycle threshold (Ct) value of the Envelope (E) gene of SARS-CoV-2 tested in triplicate

253 and plotted over time. Patient 1 was unable to provide sufficient sample volume for five

254 readings and was only tested up to 24 hours after the initial time of collection.